Facebook
Messenger
Twitter
LinkedIn
Email
Print
Monoclonal Antibodies: Update on COVID-19 Experimental Therapy
Share this:
Current experimental treatments for COVID-19 focus on two targets: the virus or the immune system. On the immune system side, the number of experimental treatments is growing. The vast majority are called monoclonal antibodies.
This type of drug is not new, and many are currently approved to treat conditions such as cancer or rheumatoid arthritis. But some are being developed from scratch to boost the initial immune response for patients who are at risk of severe COVID-19 disease.
These experimental drugs may provide patients with a way to get ahead of the virus and help manage the strain on hospital intensive care services. But what are monoclonal antibodies?
Read more about this crucial tool in the fight against COVID-19 in Discovery's Edge, Mayo Clinic's research magazine offering insight into the process and progress of medical science at the world's largest group medical practice.
Make a gift now to help transform the future of health care today.
Dick Buell’s goal is simple and selfless: “To help as many people as I can.”
Larry Connor will be one of four civilians from around the world to take part in the flight.
Larry Connor has participated in more than 1,000 hours of professional astronaut training, as well as Mayo Clinic instruction for the mission’s research component. That preparation, he feels, will contribute to a successful 10-day mission. In addition to the research materials, he's also bringing a few trinkets along with him to space on behalf of others.